IC
CMMB

Ikarian Capital’s Chemomab Therapeutics CMMB Stock Holding History

Ikarian Capital’s Portfolio CMMB Stock Details CMMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$83.9K Hold
51,793
– – 0.01% 147
2026
Q1 		$81.3K Hold
51,793
– – 0.01% 151
2025
Q4 		$85.5K Sell
51,793
-1,469
-3% -$3.9K 0.01% 164
2025
Q3 		$140K Sell
53,262
-1
-0% -$4 0.01% 157
2025
Q2 		$247K Hold
53,263
– – 0.05% 106
2025
Q1 		$232K Hold
53,263
– – 0.03% 134
2024
Q4 		$386K Sell
53,263
-85
-0.2% -$537 0.05% 136
2024
Q3 		$335K Hold
53,348
– – 0.05% 125
2024
Q2 		$196K Hold
53,348
– – 0.03% 106
2024
Q1 		$166K Hold
53,348
– – 0.02% 128
2023
Q4 		$109K Hold
53,348
– – 0.01% 126
2023
Q3 		$191K Hold
53,348
– – 0.02% 123
2023
Q2 		$280K Sell
53,348
-5,829
-10% -$36.8K 0.04% 107
2023
Q1 		$342K Sell
59,177
-19,171
-24% -$150K 0.08% 100
2022
Q4 		$1M Buy
78,348
+16,874
+27% +$146K 0.24% 51
2022
Q3 		$612K Sell
61,474
-5,552
-8% -$71.5K 0.12% 77
2022
Q2 		$992K Hold
67,026
– – 0.18% 76
2022
Q1 		$1.29M Buy
67,026
+710
+1% +$14K 0.17% 88
2021
Q4 		$1.83M Sell
66,316
-5,000
-7% -$177K 0.27% 70
2021
Q3 		$3.16M Sell
71,316
-1,318
-2% -$80.2K 0.22% 101
2021
Q2 		$5.53M Buy
+72,634
New +$7.1M 0.45% 62

Other funds holding CMMB

Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
KPWS
Kestra Private Wealth Services Austin, Texas $9.1B AUM 32.09% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $133B AUM 43.5% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
PIP
Philadelphia Investment Partners Voorhees, New Jersey $161M AUM
Lido Advisors
Lido Advisors Los Angeles, California $36.8B AUM 26.6% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Ikarian Capital's CMMB Position: Q2 2026 in Review

Ikarian Capital held its Chemomab Therapeutics (CMMB) position steady in Q2 2026 at 51,793 shares worth $83.9K. The position accounts for 0.01% of the portfolio, ranked #147.

Ikarian Capital first reported a position in CMMB in Q2 2021 and has held it in 21 quarters since. The position peaked at $5.53M in Q2 2021. 13 funds tracked by Wall St. Rank hold CMMB as of Q2 2026.

  • Ikarian Capital held 51,793 shares of Chemomab Therapeutics worth $83.9K as of Q2 2026.
  • Ikarian Capital left its Chemomab Therapeutics share count unchanged in Q2 2026.
  • Chemomab Therapeutics made up 0.01% of Ikarian Capital's portfolio in Q2 2026, its #147 holding.
  • Ikarian Capital first reported a position in Chemomab Therapeutics in Q2 2021 and has held it in 21 quarters since.
  • Ikarian Capital's Chemomab Therapeutics position peaked at $5.53M in Q2 2021.
  • 13 funds tracked by Wall St. Rank held Chemomab Therapeutics as of Q2 2026.

Based on Ikarian Capital's 13F filing for Q2 2026, filed 14 Aug 2026.